Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + anlotinib + platinum-based chemotherapy
- Development stage
- Unknown
- Lead developer
- Tangdu Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Neoadjuvant therapy 1-Tang-Du Hospital-non-small cell lung cancer refers to a combination regimen evaluated in the TD-NeoFOUR clinical trial (NCT05400070) at Tangdu Hospital. The regimen consists of **sintilimab**, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor; **anlotinib**, a multi-target tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), platelet-derived growth factor receptors (PDGFR), and c-Kit; and **platinum-based chemotherapy**. This combination is designed to leverage the synergistic effects of immune checkpoint inhibition, anti-angiogenesis, and cytotoxic chemotherapy to treat resectable stage IIA-IIIB non-small cell lung cancer (NSCLC). In phase 2 studies, the regimen demonstrated high pathological complete response (pCR) and major pathological response (MPR) rates, suggesting significant efficacy in the neoadjuvant setting.
- Other names
- sintilimab + anlotinib + chemotherapyNeoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on sintilimab + anlotinib + platinum-based chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + anlotinib + platinum-based chemotherapy.